This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.
Study Type
OBSERVATIONAL
Enrollment
90
Research Site
Vojvodina, Sremska Kamenica, Serbia
Research Site
Belgrade, Serbia
Evaluate compliance rate, as assessed by investigator, after 12 months from baseline.
Time frame: 12 months
Evaluate compliance rate, assessed by investigator, after 6 months of follow up
Time frame: 12 months
Evaluate the extent of patient educational activities as assessed by patient (using patient questionnaire) after 6 and 12 months
Time frame: 12 months
Evaluate patient compliance as assessed by the patient (using patient questionnaire) after 6 and 12 months
Time frame: 12 months
Collect epidemiology data; Demographic data: age, height, weight, lifestyle, menarche, childbirth, lactation, menopausal status
Time frame: 12 months
Primary disease (breast cancer) characteristics: receptor status, disease stage
Time frame: 12 months
Disease management data: treatment/treatment changes
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.